Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
|2||Not yet recruiting||
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
† Study has passed its completion date and status has not been verified in more than two years.